ACM
STRO icon

Aquilo Capital Management’s Sutro Biopharma STRO Stock Holding History

Aquilo Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50
Closed -$916 – 16
2024
Q4 		$916 Sell
50
-76,200
-100% -$2.33M ﹤0.01% 15
2024
Q3 		$2.64M Hold
76,250
– – 2% 14
2024
Q2 		$2.23M Sell
76,250
-40,297
-35% -$1.59M 2.15% 13
2024
Q1 		$6.58M Buy
116,547
+74,482
+177% +$3.29M 4.94% 8
2023
Q4 		$1.8M Buy
+42,065
New +$1.33M 1.12% 10

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Aquilo Capital Management's STRO Position: Q1 2025 in Review

Aquilo Capital Management sold out of Sutro Biopharma (STRO) in Q1 2025, closing a stake of 50 shares — an estimated $916 sold.

Aquilo Capital Management first reported a position in STRO in Q4 2023 and held it in 5 quarters. The position peaked at $6.58M in Q1 2024. 112 funds tracked by Wall St. Rank hold STRO as of Q1 2025.

  • Aquilo Capital Management reported no remaining Sutro Biopharma position as of Q1 2025 after selling out during the quarter.
  • Aquilo Capital Management sold 50 Sutro Biopharma shares in Q1 2025, an estimated $916.
  • Aquilo Capital Management first reported a position in Sutro Biopharma in Q4 2023 and held it in 5 quarters.
  • Aquilo Capital Management's Sutro Biopharma position peaked at $6.58M in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2025.

Based on Aquilo Capital Management's 13F filing for Q1 2025, filed 15 May 2025.